ROIVANT SCIENCES LTD. Increase Decrease In Operating Lease Liability
ROIVANT SCIENCES LTD. (ROIV) reported Increase Decrease In Operating Lease Liability of -$286.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$286.00K.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$275.00K.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$786.00K.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$846.00K.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for fiscal 2026 was -$2.38M.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for fiscal 2025 was -$5.70M.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for fiscal 2024 was -$8.33M.
- ROIVANT SCIENCES LTD. increase decrease in operating lease liability for fiscal 2023 was -$8.60M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$286.00K 10-Q · filed 2026-08-06 | -$561.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.35M derived: sum of 3 quarters · filed 2026-08-06 | -$2.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$275.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$1.06M derived: sum of 2 quarters · filed 2026-05-20 | -$1.91M derived: sum of 3 quarters · filed 2026-05-20 | -$2.38M 10-K · filed 2026-05-20 |
| 2025-12-31 | -$786.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$1.63M derived: sum of 2 quarters · filed 2026-02-06 | -$2.11M 10-Q · filed 2026-02-06 | -$2.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | -$846.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$1.32M 10-Q · filed 2025-11-10 | -$1.56M derived: sum of 3 quarters · filed 2026-08-06 | -$3.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$478.00K 10-Q · filed 2026-08-06 | -$719.00K derived: sum of 2 quarters · filed 2026-08-06 | -$2.73M derived: sum of 3 quarters · filed 2026-08-06 | -$4.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$2.26M derived: sum of 2 quarters · filed 2026-05-20 | -$3.88M derived: sum of 3 quarters · filed 2026-05-20 | -$5.70M 10-K · filed 2026-05-20 |
| 2024-12-31 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06 | -$3.64M derived: sum of 2 quarters · filed 2026-02-06 | -$5.46M 10-Q · filed 2026-02-06 | -$7.63M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-09-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10 | -$3.44M 10-Q · filed 2025-11-10 | -$5.62M derived: sum of 3 quarters · filed 2026-05-20 | -$7.62M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-06-30 | -$1.82M 10-Q · filed 2025-08-11 | -$3.99M derived: sum of 2 quarters · filed 2026-05-20 | -$5.99M derived: sum of 3 quarters · filed 2026-05-20 | -$8.13M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-03-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | -$4.17M derived: sum of 2 quarters · filed 2026-05-20 | -$6.32M derived: sum of 3 quarters · filed 2026-05-20 | -$8.33M 10-K · filed 2026-05-20 |
| 2023-12-31 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10 | -$4.14M derived: sum of 2 quarters · filed 2025-02-10 | -$6.15M 10-Q · filed 2025-02-10 | -$7.94M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-09-30 | -$2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12 | -$4.15M 10-Q · filed 2024-11-12 | -$5.94M derived: sum of 3 quarters · filed 2025-05-29 | -$8.01M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-06-30 | -$2.01M 10-Q · filed 2024-08-09 | -$3.80M derived: sum of 2 quarters · filed 2025-05-29 | -$5.86M derived: sum of 3 quarters · filed 2025-05-29 | -$8.31M derived: sum of 4 quarters · filed 2025-05-29 |
| 2023-03-31 | -$1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29 | -$3.85M derived: sum of 2 quarters · filed 2025-05-29 | -$6.30M derived: sum of 3 quarters · filed 2025-05-29 | -$8.60M 10-K · filed 2025-05-29 |
| 2022-12-31 | -$2.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13 | -$4.51M derived: sum of 2 quarters · filed 2024-02-13 | -$6.81M 10-Q · filed 2024-02-13 | -$7.51M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13 | -$4.75M 10-Q · filed 2023-11-13 | -$5.45M derived: sum of 3 quarters · filed 2023-11-13 | -$9.08M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$2.30M 10-Q · filed 2023-08-14 | -$3.00M derived: sum of 2 quarters · filed 2023-08-14 | -$6.63M derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$694.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28 | -$4.33M derived: sum of 2 quarters · filed 2023-06-28 | -$6.87M 10-K · filed 2023-06-28 | |
| 2021-12-31 | -$3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-02-13 | -$6.17M 10-Q · filed 2023-02-13 | ||
| 2021-09-30 | -$2.54M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |